SciSparc Ltd. announced that shareholders of N2OFF, Inc. have approved the proposed acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd. The approval was granted at a special meeting of N2OFF stockholders held on September 25, 2025, clearing a key path toward completing the transaction. Under the agreement, N2OFF will acquire full ownership of MitoCareX, a drug discovery company targeting resistant cancers such as pancreatic and non-small cell lung cancer. The deal, which includes both cash and stock considerations, is expected to close in the first half of October 2025, pending satisfaction of remaining closing conditions. Following the transaction, MitoCareX will become a wholly owned subsidiary of N2OFF and will receive financial support for its operations, including an initial $1 million investment. SciSparc disclosed the update.